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Abstract
Purpose The aim of this study is to test in a double-
blinded, randomised placebo-controlled study the effects
of a commercially available multi-strain symbiotic mix-
ture on symptoms, colonic transit and quality of life in
irritable bowel syndrome (IBS) patients who meet Rome
III criteria.
Background There is only one other double-blinded RCTon
a single-strain symbiotic mixture in IBS.
Methods This is a double-blinded, randomised placebo-
controlled study of a symbiotic mixture (Probinul, 5 g
bid) over 4 weeks after 2 weeks of run-in. The primary
endpoints were global satisfactory relief of abdominal
flatulence and bloating. Responders were patients who
reported at least 50 % of the weeks of treatment with
global satisfactory relief. The secondary endpoints were
change in abdominal bloating, flatulence, pain and urgency by
a 100-mm visual analog scale, stool frequency and bowel
functions on validated adjectival scales (Bristol Scale and
sense of incomplete evacuation). Pre- and post-treatment co-
lonic transit time (Metcalf) and quality of life (SF-36) were
assessed.
Results Sixty-four IBS patients (symbiotic n032, 64 %
females, mean age 38.7±12.6 years) were studied. This sym-
biotic mixture reduced flatulence over a 4-week period of
treatment (repeated-measures analysis of covariance, p<0.05).
Proportions of responders were not significantly different be-
tween groups. At the end of the treatment, a longer rectosig-
moid transit time and a significant improvement in most SF-36
scores were observed in the symbiotic group.
Conclusions This symbiotic mixture has shown a beneficial
effect in decreasing the severity of flatulence in IBS
patients, a lack of adverse events and a good side-effect
profile; however, it failed to achieve an improvement in
global satisfactory relief of abdominal flatulence and bloat-
ing. Further studies are warranted.
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Introduction
Irritable bowel syndrome (IBS) is a common gastrointestinal
disorder characterised by abdominal pain or discomfort and
altered bowel habits [1]. The aetiology of IBS is still poorly
understood, and different pathophysiological mechanisms
have been proposed: alterations in gut motility, small-
bowel bacterial overgrowth, microscopic inflammation, vis-
ceral hypersensitivity and changes related to the brain–gut
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axis [1]. On the basis of these different aetiopathological
hypotheses, a variety of therapies have been tested in IBS
patients to improve their symptoms without reaching a
complete resolution [2].
In theory, certain probiotics, at a right dose and in the
appropriate formulation, can help restore the proper balance
of the intestinal microbiota, leading to a better digestive and
intestinal function and possibly improve gastrointestinal
symptoms [3]. A mixture of probiotics and prebiotics,
namely symbiotic, should exert a synergistic benefit by the
enhancement of the probiotic organisms by the selective,
coadministered prebiotic substrate [4].
Most of the previous studies testing the effects of pro-
biotics in IBS showed mixed results largely related to meth-
odological limitations, such as the use of different probiotic
bacteria in each study and the use of heterogeneous and not
clearly defined study population. However, despite consid-
erable limitations, recently several randomised trials com-
paring the effects of probiotics vs placebo in IBS showed
some interesting positive effects on many gastrointestinal
symptoms, especially bloating and flatulence [5–8]. Taken
together, the data coming from studies on probiotics in IBS
patients demonstrated that not all probiotics are the same
and that the effect of a specific probiotic cannot be extrap-
olated to another probiotic strain [9–11]. The mechanisms of
such benefits are unfortunately still poorly understood. One
of the hypotheses is supported by the clear recognition that
IBS may in fact be induced by bacterial gastroenteritis (post-
infectious IBS) [12] and that qualitative changes in the flora,
as well as an immune dysfunction, may be more prevalent in
IBS in general [13]. Furthermore, it has been shown that
the interaction between commensal microbiota and the
host might have an important role in the modulation of
the gut sensory–motor function [14]. The rationale for
choosing this symbiotic mixture for our study was based
on several reasons: the product is already available on
the market, has a record of safe human consumption and
to our knowledge there is only one other double-blinded
RCT on a single-strain symbiotic mixture which was
performed regarding IBS [15]. Thus, the hypothesis of
our study was that the beneficial effects of manipulation
of the intestinal microbiota in patients with IBS, through
a symbiotic mixture, can result in an improvement of
abdominal symptoms, i.e. bloating and flatulence, a
change in colon transit time and an improvement in the
quality of life.
Aim
Our aim was to test in a double-blinded, randomised
placebo-controlled study the effects of a commercially avail-
able symbiotic mixture in IBS patients.
Methods
Study population
Sixty-four IBS patients were recruited from an outpatient
clinic, which is only devoted to gastrointestinal functional
disorders. The study protocol had previously been approved
by the ethical committee of Federico II University of Naples
and therefore had been performed in accordance with the
ethical standards laid down in the 1964 Declaration of
Helsinki. All participants signed a consent form prior to
being enrolled in the study.
The diagnosis of IBS was made on the basis of the Rome
III criteria [16] together with the exclusion of any other
organic disease. The severity of IBS was scored using the
validated Functional Bowel Disorders Severity Index
(FBDSI), developed by Drossman et al., which provides
an easy-to-use scale to appraise illness severity in this com-
plex group of patients. It is comprised of three variables:
current pain (by 0–100 visual analog scale (VAS)), diagno-
sis of chronic abdominal pain and the number of physician
visits within the past 6 months. Severity was rated as mild
(1–36 points), moderate (37–110 points) and severe (≥111
points). Details of the index calculation are presented in the
original article [17].
The eligibility criteria included females and males be-
tween the ages of 18 and 75 having the ability to understand
and the willingness to comply to the study procedures;
females with childbearing potential were required to have
a negative pregnancy blood test within 48 h of the two
colonic transit studies. They were also required to have an
average daily abdominal bloating score or flatulence ≥24 on
a 100-mm VAS during the 2-week run-in period. Patients
were excluded if they had serious, unstable medical condi-
tion, insulin-dependent diabetes mellitus, major psychiatric
diagnosis, previous history of drug or alcohol abuse
6 months prior to screening, a diagnosis of lactase deficien-
cy or if symptoms resolved with lactose-free diet and if they
had undergone previous abdominal surgery except appen-
dectomy, caesarean section, tubal ligation, laparoscopic cho-
lecystectomy, hysterectomy or abdominal wall hernia repair.
They were also excluded if they currently used medications
that may alter gastrointestinal motility, or long-term anti-
biotics or proton pump inhibitors. Patients were also care-
fully interrogated on use of over-the-counter medication
within 3 days of transit studies and antibiotic use 1 month
prior to screening.
Concomitant medications
The following medications were permitted during the course
of the study, as long as they had been used at a constant
dosage and were commenced at least 1 month prior to the
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start of the 2-week run-in period: birth control pill or depot
intramuscular contraceptive preparation, oestrogen–proges-
terone replacement therapy, L-thyroxine, low-dose antide-
pressants (up to 25 mg day−1 of amitriptyline, nortriptyline
or selective serotonin reuptake inhibitor) or antihyperten-
sives in the diuretic, angiotensin-converting enzyme inhib-
itor or angiotensin II inhibitor classes.
Study design
A parallel-group, double-blinded, placebo-controlled study
with a total of 64 patients being randomised to either place-
bo (n032) or symbiotic (n032) was planned. Randomisa-
tion was carried out according to a computer-generated,
blocked randomisation list independent of the research
group (Statistical Department of Istituto Di Sanità, Roma)
and with a concealed block size of 4. The patients, the
investigators, the doctors and the study nurse were blinded
using randomisation codes, which were kept confidential
until the end of data analysis. Eligible patients were required
to pursue a baseline 2-week run-in period recording daily
symptoms by means of a diary and, followed by a 4-week
treatment period (Fig. 1). All patients underwent colonic
transit measurement and filled in the quality of life ques-
tionnaire at the end of run-in and of the treatment phase.
Study treatments
The symbiotic mixture (Probinul, CaDi Group, Rome, Italy)
contains lyophilised bacteria (5×109 Lactobacillus plantarum,
2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lac-
tobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109
Bifidobacterium longum, 1×109 Lactobacillus acidophilus,
1×109 Lactobacillus salivarus and 1×109 Lactobacillus spor-
ogenes and 5×109 Streptococcus termophilus), prebiotic inu-
lin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant
starch. The study preparation was provided in a powder form
(5-g sachets) containing the symbiotic mixture or the matching
placebo (CaDi Group, Rome, Italy) comparable in colour,
texture and taste to the symbiotic mixture. The patients were
instructed to ingest the investigational powder preparation
twice daily, preferably in the morning and in the evening far
from meals, dissolving it in water.
Assessment of symptoms and bowel functions
Patients filled in a daily diary to evaluate stool frequency,
bowel function and symptoms. Bowel function was assessed
on validated adjectival scales: stool consistency by Bristol
stool form scale [18–21], and the sensation of incomplete
evacuation was evaluated by a binomial answer (yes or no).
Bowel symptoms were bloating, sensation of flatulence,
pain and faecal urgency which were assessed on 100-mm
VAS. Moreover, they tracked the intake of all medications
during the trial. If they received antibiotics for acute infec-
tions (for example bacterial throat or urinary infections), the
symptom data for the time of antibiotic administration and
1 week after completion were excluded from analysis and
the treatment period was prolonged to ensure availability of
the requisite number of weeks of study treatment. At the end
of each week, patients were required to record a weekly
response to a question on the global satisfactory relief of
abdominal bloating and sensation of flatulence by a single
statement (yes or no).
Diet registration
The patients recorded all the food they had eaten during two
weekdays in the diary during the run-in and the treatment
period. Nutrients were manually calculated.
Compliance
The patients reported the daily consumption of the study
product in the diary. The compliance was calculated as
percent of planned ingestion of the study product, and
days 
0 14 42








Washout medications Daily symptoms diary
Fig. 1 Schematic presentation
of the study design
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compliance above 80 % was set as a minimum requirement
in order to be regarded as acceptable.
Tolerability and safety
Tolerability and safety were assessed by recording all
reported adverse events.
Assessment of colonic transit time
Total and segmental colonic transit time (CTT) was assessed
according to Metcalf et al. [22]. The abdominal X-rays were
recorded at 9:00 AM on the day after 3 days ingestion of 20
differently shaped radioopaque markers at 9:00 AM each day
(Marquat Genie Biomedical, Boissy-St Léger, France). The
X-rays were taken using a rapid high-kilovoltage technique to
reduce radiation exposure to less than 0.5 mSv. The markers
located to the right of the vertebral spinous process and above
an imaginary line running from the fifth lumbar vertebra to the
pelvic outlet were assigned to the right colon; those left of the
vertebral spinous process and above an imaginary line running
from the fifth lumbar vertebra to the anterior superior iliac
crest were assigned to the left colon; and those below an
imaginary line running from the pelvic brim on the right to
the anterosuperior iliac crest on the left were judged to be in
the rectosigmoid. Total and segmental CTT (left side, right
side and rectosigmoid) were calculated according to the for-
mula: Colonic transit (hours)01.2×number of markers. A
Spearman correlation explored the association between Bris-
tol stool form scale and colonic transit time and any significant
change in symptoms.
Assessment of quality of life
Before the start of the randomisation period and at the end of
it, the patients answered a self-administrated quality of life
questionnaire, SF-36 (validated Italian version) [23]. This is
a generic measure of perceived health status, widely used in
medical and health service research, that incorporates
behavioural functioning, subjective well-being and percep-
tion of health by assessing eight health concepts: physical
function (how patients perceive their ability to perform
physical tasks), role-physical (how patients perceive their
ability to fulfil their life role physically), bodily pain (how
patients perceive their level of pain), general health (how
patients perceive their overall health and well-being), vital-
ity (how patients perceive their level of ‘energy’), social
function (how patients perceive their ability to participate
in social activities), role-emotional (how patients perceive
their ability to fulfil their life role emotionally) and mental
health (how patients perceive their emotional and psycho-
logical well-being). The scores on all scales range from 0 to
100, with higher scores reflecting better health.
Statistical analysis
The primary endpoint for analysis in this study was the
global satisfactory relief of bloating and flatulence. The
primary analysis was a comparison by Fisher's exact test
of the proportion of responders treated with symbiotic mix-
ture vs placebo. Responders were defined as individuals
whose response to the weekly global satisfactory relief
questions was yes on at least 50 % of weekly assessment
of the 4-week randomisation [7].
The secondary endpoints included severity of VAS scores
for symptoms and bowel function scores. The daily diary
was used to appraise the bowel function scores (frequency,
consistency and the proportion of days with the sense of
incomplete evacuation) and the severity of individual symp-
toms (abdominal bloating, sensation of flatulence, pain and
urgency). The VAS symptom scores are rounded to the
nearest integer in millimetres. The adjectival scales for stool
consistency (Bristol stool form scale) were recorded as
numerical values. The data on bowel function scores and
VAS scores of individual symptoms were summarised
weekly as the means and standard errors in each treatment
group.
In the secondary analysis, the comparison of the two
groups focused on contrasting week-by-week symptoms
and bowel function scores during the treatment period using
a repeated-measures analysis of covariance (ANCOVA)
model with the corresponding value at baseline as the cova-
riate. Age was also included as a covariate for analyses of
the symptoms. ANCOVA was used to account for the po-
tential effects of differences in the mean baseline measure-
ments and scores between the two treatment groups [7].
The remaining total and segmental CTT and eight-item
SF-36 scores were compared within groups with paired t test
or Wilcoxon signed-rank test for paired comparison samples,
as warranted. Post-treatment between group values were com-
puted based on two-sample t test or Mann–Whitney U (M-W)
for unpaired comparisons, as warranted.
Data are presented as mean (±standard error (SE)), unless
otherwise indicated; Significance was expressed at p<0.05
level. The SPSS software package for Windows (release
18.0; SPSS Inc, Chicago, IL, USA) was used for statistical
analysis.
From previous clinical trials [24, 25] that considered the
intention to be able to detect a 30 % difference in the
proportion of responders between the two groups with
80 % power at a00.05, a minimum of 60 patients would
be required. Our study was designed to include 64 patients,
32 per treatment group. Knowing that this was a very
optimistic calculation based on previous clinical trials, we
also planned to perform sample size calculations for future
studies based on the proportion of responders in our treat-
ment group.
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Results
Demographic characteristics
A total of 83 IBS patients were enrolled to obtain the
calculated sample size (n064). During the run-in, 15 IBS
patients were not subsequently randomised: ten withdrew
their consent, one had concomitant acute diseases (throm-
bosed external haemorrhoids), one underwent PPI therapy,
two failed to fulfil the severity criteria for bloating or flatu-
lence and one was positive to the pregnancy test 48 h before
the first transit study.
During the randomisation period, four drop-outs occurred
(Fig. 2). All patients were replaced to obtain the calculated
sample size.
No differences were found in age, gender, FBDSI and
predominant bowel habits between symbiotic and placebo
groups. At baseline, the bloating score and the sensation of
flatulence were similar in both groups (Table 1).
Symptoms and bowel function
Primary outcomes Responders for abdominal bloating were
46.9 % (15/32) for the symbiotic group vs 65.6 % (21/32)
for the placebo group (Fisher's exact test, p00.21) and for
sensation of flatulence were 50 % (16/32) for the symbiotic
group vs 62.5 % (20/32) for the placebo group (Fisher's
exact test, p00.45).
Secondary outcomes The score of flatulence was significantly
lower with symbiotic mixture compared to placebo during the
week-by-week comparisons of treatment period (repeated-
measures ANCOVA, p00.038). The symptoms of bloating,
pain and urgency did not show any significant difference in the
two groups during the treatment period (Fig. 3).
There were no statistically significant differences
detected for bowel function during the week-by-week
comparisons of treatment period (repeated-measures






1 lack of effect
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32 placebo 
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1 PPI therapy 
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Fig. 2 Flow chart
demonstrating the number of
patients in the different phases
of the study
Int J Colorectal Dis (2013) 28:349–358 353
proportion of days with the sense of incomplete evacuation
p00.552).
Diet
Quality and quantity of food intake were unchanged along the
entire study: run-in and randomisation period (data not shown).
Compliance
The compliance was >95 % in both groups as analysed from
the study diaries. Five of the 64 participants (one in placebo
and four in the treated group) required antibiotic therapy
during the study period for infection (cystitis, upper respi-
ratory infection and prophylaxis for dental work) and ad-
hered to protocol instructions. One patient from each
treatment group used a loperamide tablet (average use, two
tablets; range 1–3) as predefined rescue medication for
severe diarrhoea during the 6-week trial. Other medications
were: milk of magnesia (two patients for 1 day), paraceta-
mol (two patients for 2 days), prednisone (one patient for
5 days), budesonide inhaler (one patient for 6 days) and
ketoprofen (one patient for 1 day).
Tolerability and safety
There were no adverse events noted with the use of this
symbiotic mixture and/or placebo treatment.
Colonic transit time
In the run-in period, no significant differences were
found in total, right, left and rectosigmoid transit time








Diarrhoea, n (%) 9 (28.1) 14 (43.8)
Constipation, n (%) 13(40.6) 12 (37.5)
Mixed, n (%) 10 (31.3) 4 (12.5)
Undetermined, n (%) 0 (0.0) 2 (6.3)
Bloating VAS score 40.7±3.7 42.6±2.8
Flatulence VAS score 36.4±2.9 35.4±2.7
Values are expressed as mean±SE
Fig. 3 VAS scores of bloating, flatulence, abdominal pain and urgency during the run-in and treatment period in symbiotic and placebo groups.
(Mean values±SE; repeated-measures ANCOVA, p<0.05)
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(M-W, p00.4, p00.9, p00.5 and p00.3, respectively).
Total and segmental CTT did not change from pre-
treatment to post-treatment period within symbiotic and
placebo group (Wilcoxon signed-rank test for paired
comparisons; Fig. 4).
In post-treatment period, symbiotic group compared to
placebo group showed a longer rectosigmoid transit time
that just failed to reach statistical significance (symbiotic
14.3±2.5 vs placebo group 8.9±1.9 h (mean±SE), M-W,
p00.06), while no differences were found in total, right and
left CTT.
A significant Spearman correlation (Rs) was found among
total transit time and stool consistency (Bristol Scale score) at
run-in and at the end of the study (Rs0−0.37, p00.003 and
Rs0−0.32, p00.02). No significance was found in the
Spearman correlation between the change of flatulence
score (baseline to last week of treatment) and the change
in total colonic transit time (baseline to end of treatment;
Rs00.03).
Quality of life
Figure 5 shows the eight-item SF-36 scores for symbiotic
and placebo group pre- and post-treatment. All items of the
SF-36 questionnaire, a part vitality domain, significantly
improved from pre-treatment to post-treatment period within
symbiotic group, while in placebo group, only three domains,
role-physical, bodily pain and mental health, reached a signif-
icant improvement from pre-treatment to post-treatment period.
However, none of the changes observed differed significantly
between the groups.
Discussion
This is the first randomised, double-blinded, placebo-
controlled study investigating this particular commercially
available symbiotic mixture in patients with IBS. Our results
demonstrated a significant beneficial effect of the symbiotic
mixture in decreasing the severity of flatulence in IBS
patients. At the end of the treatment study, an increased
colonic transit time in rectosigmoid and a significant im-
provement in most SF-36 scores were observed in IBS
patients, who ingested the symbiotic mixture. However,
there were no significant differences in the predefined pri-
mary endpoints, focused on the global satisfactory relief of
bloating and flatulence. The symbiotic mixture and the
placebo product were both well tolerated by the participants
in the study, with no adverse events. IBS is a heterogeneous
disorder, consisting of a number of bothersome symptoms
that we are presently not able to treat efficaciously.
As recently shown, the most bothering symptom after
abdominal pain is bloating, including abdominal distension
and gas. Their presence is a frequent reason to seek medical
care [26] and is often associated with a reduced quality of
life. Several studies targeting the intestinal microbiota for
treatment of functional GI symptoms reported a prominent
beneficial effect of these interventions on bloating symp-
toms and the sensation of flatulence [6–8].
In recent years, the interest on the efficacy of probiotics
in IBS led to extensive systematic reviews and meta-
analyses studies focused on this topic [9–11, 27, 28]. One
of these systematic reviews analysed a total of 16 rando-
mised controlled trials and found that B. infantis was the
Fig. 4 Total and segmental
colonic transit time in patients
with irritable bowel syndrome
pre- and post-treatment with
symbiotic mixture or placebo
(mean values±SE)
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only strain that could show any positive effect upon the
symptoms, in two appropriately designed studies [10]. An-
other one, analysing the continuous data, demonstrated that
combinations of probiotics improved symptoms in patients
with IBS, and in addition, higher quality studies reported a
more modest treatment effect, compared to lower quality
studies [11].
Our finding, of a significant decrease in the severity of
flatulence in IBS patients treated with the symbiotic mixture
compared to the IBS patients treated with the placebo over a
4-week period of treatment, suggests a beneficial effect of
this particular combination of prebiotics and probiotic in
IBS patients. However, contrary to our hypothesis, the pres-
ent study was not able to show an improvement of other
investigated outcomes, especially those of the primary out-
come (global satisfactory relief in symptoms of bloating and
flatulence). This result may be related to the intrinsic limi-
tations of the study design which was the first study on this
symbiotic mixture, with a small number of patients that
leads to the lack of statistical power (type 2 error) as well
as to the inclusion of a heterogeneous IBS population. The
primary outcome, furthermore, is a multidimensional out-
come that is influenced by a number of factors, including
coping mechanisms and psychological status, which may
not be directly related to symptoms severity [29]. It is
noteworthy that most domains in the SF-36 QoL question-
naire have improved in the active group with symbiotic
treatment but only a few in the placebo group.
There are no current studies available that could prove
unambiguously the mode of action of probiotics, which can
be clearly linked to the improvement of IBS and its symp-
toms. As an attempt to investigate the possible effects of the
symbiotic mixture on IBS symptoms, transit time was stud-
ied. At the end of treatment, patients treated with the sym-
biotic mixture showed a lengthening in rectosigmoid transit
time that just failed to reach a statistical significance. The
colonic transit time significantly correlated with the increase
in stool consistency measured by Bristol Scale score. This
may result in reduced aborad movement of stool and, pos-
sibly, the reduced flatulence [7].
Although it seems biologically plausible that modifica-
tion of the gut flora could have an effect on IBS-related
symptoms such as the flatulence sensation by modifying gas
production (colonic milieu) and gut transit, further studies
are needed to explore the mechanism of the observed re-
tarded transit of stool and the potential effects on colonic
sensation and colonic fermentation of nutrients reaching the
colon. In the literature, several mechanisms have been sug-
gested to explain the efficacy of probiotics in IBS, such as
the influence of intestinal luminal environment, the mainte-
nance of epithelial and mucosal barrier function and the
modulation of mucosal or systemic immune system includ-
ing both innate and adaptive immune systems [30–32].
Although it might be too early to make a conclusion of
whether these mechanisms could be adapted to the patho-
genesis of IBS, there is, however, a growing body of evi-
dence that supports the association of gut inflammation/
immunity and IBS and that define the roles of probiotics
in the pathogenesis of IBS. Another important issue is that
in the symbiotic mixture administered in the present study,
there are also prebiotics and their exact role in IBS remains
unclear due to the paucity of trials evaluating their treatment
efficacy [33]. Prebiotics, at least in theory, may globally
enhance the functions of probiotics, augment the effects of
beneficial commensal bacteria of the gut and assist in the
creation of an inhospitable environment for the proliferation
of pathogenic bacteria [34]. As shown in Fig. 3, it is inter-
esting that flatulence seems to worsen initially in the sym-
biotic group and then it improves. This is potentially an
important point of interest. In fact, prebiotic, such as inulin,
could initially cause an increase in flatulence delivering, as
it does, unabsorbed carbohydrate to colonic bacteria.
Fig. 5 The mean SF-36 scale
scores for IBS patients who
underwent symbiotic mixture or
placebo treatment (mean values
±SE). § p<0.05 pre- vs post-
treatment using paired t test
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However, it is already known that colonic bacteria adapt to
new substrates and will metabolise them more effectively
over time, showing the beneficial effects of reducing flatu-
lence as the colonic flora adapts.
To our knowledge, there is another randomised, double-
blinded, placebo-controlled study that investigated a symbi-
otic mixture in IBS [15], but it studied only a single-strain
probiotic and the placebo consisted of the same mixture
with inactivated probiotic, leading to a possible misinterpre-
tation of the results for a role due to the prebiotic. Although
we did not perform any microbiological analyses of the
stools in the present study, it has been recently shown that
this particular symbiotic was able to modify the gut flora in
healthy volunteers compared to placebo [35].
There are several limitations of this study. First of all, the
study population was not sufficiently large enough for a
subgroup analysis of IBS subtypes. We were, therefore,
unable to show whether some IBS subtypes would actually
benefit more from the consumption of the symbiotic mixture
than the others. Additionally, the duration of the study was
perhaps too short. We chose a 4-week period of treatment on
the assumption that strict exclusion criteria for concomitant
medications should be followed to avoid potential con-
founders, but it would be of specific value to explore wheth-
er patients benefit more from a longer consumption of this
symbiotic mixture and also whether this symbiotic mixture
needs to be given on a cyclic schedule because of the
temporary modification of the faecal flora [36].
In conclusion, the symbiotic mixture (Probinul) failed to
achieve an improvement in primary endpoints, i.e. global
satisfactory relief of abdominal flatulence and bloating.
Among the secondary endpoints, it did demonstrate a ben-
eficial effect in decreasing the severity of flatulence in IBS
patients. The mixture, however, showed a lack of any ad-
verse events and a good side-effect profile. Further studies
on a larger number of patients are indeed needed to confirm
whether this symbiotic mixture might be an effective treat-
ment option in IBS.
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